Int J Med Sci 2020; 17(13):1864-1870. doi:10.7150/ijms.44443
Resveratrol reduces inflammation-related Prostate Fibrosis
1. Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
2. Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania, 95123 Catania, Italy.
3. Research Centre "The Great Senescence", University of Catania, 95126 Catania, Italy.
4. UOSD Medicina Interna Ambulatorio Andrologia & Endocrinologia ARNAS-Garibaldi, 95123 Catania, Italy.
Vicari E, Arancio A, Catania VE, Vicari BO, Sidoti G, Castiglione R, Malaguarnera M. Resveratrol reduces inflammation-related Prostate Fibrosis. Int J Med Sci 2020; 17(13):1864-1870. doi:10.7150/ijms.44443. Available from http://www.medsci.org/v17p1864.htm
Inflammation-related prostate fibrosis (PF) is strongly associated with impaired urethral function and lower urinary tract symptoms (LUTS) severity. The aim of this study was to investigate the effects of RSV in patients with small prostate volume and LUTS. Sixty-four patients with PF were randomized either to RSV therapy (group A= 32 patients) or placebo (group B= 32 patients). At baseline (T0) and after 2-months (T2), patients of both groups underwent administration of NIH-Chronic Prostatic Symptom Index (NIH-CPSI) and International Prostate Symptom Score (IPSS) questionnaires for prostatitis and LUTS, respectively, and Expressed Prostatic Secretion (EPS) assays. After two months, only, group A patients treated with RSV showed significant symptomatic improvement of all NIH-CPSI and IPSS subscale scores, as well as a better EPS assay after prostate massage, in terms of high amount of prostatic volume and reduced white blood cells counts. Our data suggested pharmacological advantage after 2-month treatment with RSV in selected patients with PF for the treatment of voiding and storage complaints.
Keywords: Prostate fibrosis, small prostate volume, Meares and Stamey test, LUTS, IPSS, NIH-CPSI, Resveratrol